Oral News and Research

RSS

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Estrogen therapy improves low bone density due to anorexia nervosa in teenage girls with the disease when given as a patch or as a low oral dose that is physiological.

6 Jun 2011

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.

6 Jun 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.

6 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Formoterol medication shows promise for improving fat and protein metabolism in men

Formoterol, a new generation asthma medication, shows great promise for improving fat and protein metabolism, say Australian researchers, who have tested this effect in a small sample of men. The researchers presented their results on Saturday 4 June 2011 at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

Safety of birth control pills under scrutiny

Bayer’s oral contraceptive pills are being reviewed by regulators after some studies suggested they may cause more blood clots than competing medicines.

5 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011

Study: Only one third of people in the UK always wash their hands after using the toilet

With E.coli once again in the headlines, research by global hygiene experts, Initial, shows that only one in three Brits wash their hands after a visit to the toilet. As E.coli bacteria can spread from person to person by what is known as the 'faecal-oral' route, the transference possibilities of bacteria are immense.

4 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Genentech, a member of the Roche Group and Astellas Pharma US, Inc., today announced results of EURTAC, the first Phase III study with Tarceva in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC).

4 Jun 2011

American College of Gastroenterology offers resources on foodborne illness, tips for food safety

For consumers in the United States concerned by the outbreak of E. coli in Europe, the American College of Gastroenterology offers background on foodborne illness, tips for food safety, and expert insight from its resources on digestive health on what to do in the case of foodborne illness.

4 Jun 2011

Sexual pleasure among young adults linked to healthy psychological and social development

Sexual pleasure among young adults (ages 18-26) is linked to healthy psychological and social development, according to a new study by researchers at the Johns Hopkins Bloomberg School of Public Health.

4 Jun 2011

Study assesses public's willingness to consider pre-exposure prophylaxis for HIV prevention

In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.

4 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators.

4 Jun 2011

Preclinical study: Combination therapy of SPX-106 and D-tagatose reduces triglycerides and cholesterol

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.

3 Jun 2011

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

ARIAD Pharmaceuticals, Inc. today announced initial clinical findings on ponatinib in patients with advanced acute myeloid leukemia (AML).

3 Jun 2011

Health law gets mixed reception in Ohio federal appeals court

A panel of federal appellate judges heard oral arguments Wednesday regarding whether the Obama administration can — under the Constitution — require Americans to buy health insurance. A key issue for the judges to determine is whether the plaintiffs have legal standing to sue after one said she recently purchased coverage from her employer. The case was initially brought by the Michigan-based Thomas More Law Center.

3 Jun 2011

Oral News and Research

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Formoterol medication shows promise for improving fat and protein metabolism in men

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Bharat Biotech announces the pricing for ROTAVAC vaccine

Safety of birth control pills under scrutiny

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Study: Only one third of people in the UK always wash their hands after using the toilet

Researcher to evaluate new approach for treatment of triple-negative breast cancer

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

American College of Gastroenterology offers resources on foodborne illness, tips for food safety

Sexual pleasure among young adults linked to healthy psychological and social development

Study assesses public's willingness to consider pre-exposure prophylaxis for HIV prevention

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

Preclinical study: Combination therapy of SPX-106 and D-tagatose reduces triglycerides and cholesterol

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

Health law gets mixed reception in Ohio federal appeals court

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News